Liquidia, Pharmosa Biopharm Have Announced An Exclusive Licensing Agreement In North America For L606, An Inhaled, Sustained-release Formulation Of Treprostinil; Liquidia Will Pay $10M In Upfront And $215M In Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Liquidia and Pharmosa Biopharm have entered into an exclusive licensing agreement for the development and commercialization of L606 in North America. Liquidia will pay $10M upfront and $215M in milestone payments. L606 is an inhaled, sustained-release formulation of treprostinil, currently under clinical trial for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
June 28, 2023 | 9:52 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Liquidia's new licensing agreement with Pharmosa Biopharm for L606 could potentially increase its revenues if the drug proves successful in clinical trials. However, the upfront and milestone payments represent a significant financial commitment.
The licensing agreement could potentially increase Liquidia's revenues if L606 proves successful in clinical trials and receives regulatory approval. However, the upfront payment of $10M and milestone payments of $215M represent a significant financial commitment from Liquidia, which could impact its short-term financial stability.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100